Lina Liang

Dr. Lina Liang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JLJiaxian Li
Jiaxian Li
WZWei Zhou
Wei Zhou
LLLina Liang
Lina Liang
YLYamin Li
Yamin Li
KXKai Xu
Kai Xu
YJYu Jin
Yu Jin
Background: Electrical activity has a crucial impact on the development and survival of neurons. Numerous recent studies have shown that noninvasive electrical stimulation (NES) has neuroprotective action in various retinal disorders.Objective: To systematically review the literature on in vivo studies and provide a comprehensive summary of the neuroprotective action and the mechanisms of NES on retinal disorders.Methods: Based on the PRISMA guideline, a systematic review was conducted in PubMed, Web of Science, Embase, Scopus and Cochrane Library to collect all relevant in vivo studies on “the role of NES on retinal diseases” published up until September 2023. Possible biases were identified with the adopted SYRCLE’s tool.Results: Of the 791 initially gathered studies, 21 articles met inclusion/exclusion criteria for full-text review. The results revealed the neuroprotective effect of NES (involved whole-eye, transcorneal, transscleral, transpalpebral, transorbital electrical stimulation) on different retinal diseases, including retinitis pigmentosa, retinal degeneration, high-intraocular pressure injury, traumatic optic neuropathy, nonarteritic ischemic optic neuropathy. NES could effectively delay degeneration and apoptosis of retinal neurons, preserve retinal structure and visual function with high security, and its mechanism of action might be related to promoting the secretion of neurotrophins and growth factors, decreasing inflammation, inhibiting apoptosis. The quality scores of included studies ranged from 5 to 8 points (a total of 10 points), according to SYRCLE’s risk of bias tool.Conclusion: This systematic review indicated that NES exerts neuroprotective effects on retinal disease models mainly through its neurotrophic, anti-inflammatory, and anti-apoptotic capabilities. To assess the efficacy of NES in a therapeutic setting, however, well-designed clinical trials are required in the future.

19 January 2021 in Trials
Verified
Journal Article
Open access
PDF file
YLYamin Li
Yamin Li
LLLina Liang
Lina Liang
TSTorkel Snellingen
Torkel Snellingen
KXKai Xu
Kai Xu
YGYun Gao
Yun Gao
XYXueyan Yang
Xueyan Yang
Background: Neovascular age-related macular degeneration (nAMD) is the most common cause of irreversible vision loss and blindness among the older people aged 50 and over. Although anti-vascular endothelial growth factor (anti-VEGF) therapies have resulted in improving patient outcomes, there are limitations associated with these treatments. In China, traditional Chinese medicine (TCM) has been used to treat eye diseases for more than 2000 years. Previous studies have shown that TCM may be beneficial for nAMD patients. However, explicit evidence has not been obtained. The purpose of the present trial is to examine the efficacy and safety of the Mingjing granule, a compound Chinese herbal medicine, for nAMD patients. Methods/design: This is a double-blind, placebo-controlled, randomized trial of Mingjing granule as an add-on to intravitreous ranibizumab for nAMD. One hundred eighty nAMD patients from six hospitals in China will be enrolled according to the inclusion and exclusion criteria and randomly allocated into two groups, 90 in each. All participants will receive a 24-week treatment and then be followed up for another 24 weeks. The primary outcome is the mean change of best-corrected visual acuity at week 24 and 48 as compared to the baseline. The secondary outcomes include mean change in central retinal thickness, area of retinal hemorrhage and exudation, and TCM syndrome score, mean number of intravitreal ranibizumab injection, and total cost of the treatment. Indexes of safety include blood regular test, urine regular test, liver function test, renal function test, and electrocardiogram from baseline to weeks 24 and 48. Qualitative control and some standard operating processes will be formed throughout the trial. Any ocular or systemic adverse events will be treated suitably, and related data will be recorded accurately and completely in the case report form. Discussion: Based on previous empirical and animal laboratory studies, this study will address the question of whether Mingjing granule could contribute to improving efficacy, safety, and efficiency with need for fewer intravitreal injections of anti-VEGF, improving compliance and visual outcomes in the management of persons with nAMD. Trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn), ChiCTR2000035990. Registered on 21 August 2020.

16 December 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
YJYu Jin
Yu Jin
LLLina Liang
Lina Liang
JLJiaxian Li
Jiaxian Li
KXKai Xu
Kai Xu
WZWei Zhou
Wei Zhou
YLYamin Li
Yamin Li
Glaucoma is a pathologically irreversible eye illness in the realm of ophthalmic diseases. Because it is difficult to detect concealed and non-obvious progressive changes, clinical diagnosis and treatment of glaucoma is extremely challenging. At the same time, screening and monitoring for glaucoma disease progression are crucial. Artificial intelligence technology has advanced rapidly in all fields, particularly medicine, thanks to ongoing in-depth study and algorithm extension. Simultaneously, research and applications of machine learning and deep learning in the field of glaucoma are fast evolving. Artificial intelligence, with its numerous advantages, will raise the accuracy and efficiency of glaucoma screening and diagnosis to new heights, as well as significantly cut the cost of diagnosis and treatment for the majority of patients. This review summarizes the relevant applications of artificial intelligence in the screening and diagnosis of glaucoma, as well as reflects deeply on the limitations and difficulties of the current application of artificial intelligence in the field of glaucoma, and presents promising prospects and expectations for the application of artificial intelligence in other eye diseases such as glaucoma.

27 January 2024 in Trials
Verified
Journal Article
Open access
PDF file
WZWei Zhou
Wei Zhou
ZHZiyang Huang
Ziyang Huang
KXKai Xu
Kai Xu
YLYamin Li
Yamin Li
XLXiaoyu Li
Xiaoyu Li
LLLina Liang
Lina Liang
Background: Retinitis pigmentosa (RP) is an inherited disease characterized by a progressive loss of rod photoreceptors of the eye, leading to irreversible blindness. To date, to our knowledge, no clinical prospective studies have been undertaken that could document the effect of interventions that could reverse or reduce the progression of this disease. The application of microcurrent stimulation (ES) of the eye in the treatment of chronic eye diseases such as glaucoma and age-related macular degeneration has been used over several decades and has been reported to have beneficial effects to reduce the progression of these blinding diseases and has been supported by animal studies and smaller clinical studies, but to date, no large randomized clinical trials on the use of microcurrent therapy have been published. More recent clinical reports have also shown beneficial effects of ES on slowing the progression of RP but also lacks data from robust prospective clinical outcome studies. To our knowledge, this is the first prospective randomized study to evaluate the safety and clinical effectiveness of transpalpebral electrical stimulation (TpES) on the progression of RP. Methods: Randomized prospective study using N-of-1 trial 3 single-blind, crossover comparisons. The intervention period of each comparison is divided into treatment period and control period which are randomized arranged. Twelve participants will be strictly recruited in N-of-1 trial by the researcher in accordance with the inclusion and exclusion criteria. The main outcome of interest examined after each cycle of the 8-week intervention period is the assessment of the visual field (VF). Other variables of interest are best corrected visual acuity (BCVA), retinal function using electroretinogram (ERG), and visual function using NEI VFQ-25 questionnaire. Objective assessments of retinal changes will be undertaken using optical coherence tomography (OCT) and fundus autofluorescence (FAF). Discussion: The trial will evaluate the efficacy and safety of microcurrent stimulation on RP and provide high-quality evidence for clinical application through N-of-1 trial. Trial registration: Chinese Clinical Trial Registry; ChiCTR2300067357; https://www.chictr.org.cn/showproj.html?proj=174635. Registered on 5 January 2023

2 February 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
MGMiaoran Gao
Miaoran Gao
JZJian Zhou
Jian Zhou
NSNannan Shi
Nannan Shi
XYXiaoling Yan
Xiaoling Yan
LLLina Liang
Lina Liang
Optic nerve injury, encompassing conditions such as glaucoma, optic neuritis, and traumatic optic neuropathy, is a major cause of irreversible vision loss. Traditional broad-spectrum anti-inflammatory treatments have shown limited efficacy, highlighting the need for precision-based therapeutic approaches grounded in the underlying pathological mechanisms. As the primary immune cells of the central nervous system (CNS), microglia play a crucial role in regulating neuroinflammation following optic nerve injury. This review provides a comprehensive overview of the mechanisms governing microglial neuroinflammatory regulation, including early inflammatory signal recognition mediated by damage-associated molecular patterns (DAMPs), dynamic transcriptional networks regulating polarization between pro-inflammatory and pro-repair phenotypes, bidirectional modulation of phagocytic clearance by the complement system, and the complex multicellular interactions among microglia, astrocytes, and Müller cells. The concept of conditioning injury conditioning injury (intraocular inflammatory stimulation) has revealed the dual nature of neuroinflammatory responses: through temporal polarization shifts, microglia can both release neurotoxic mediators that worsen injury and secrete neurotrophic factors that promote axonal regeneration and myelin repair. This shift from traditional broad-spectrum anti-inflammatory strategies to precision functional modulation forms the basis for emerging therapeutic approaches, including PPARγ pathway activation, selective complement system targeting, and time-dependent modulation. We also assess the potential of advanced technologies, such as nanodelivery systems, single-cell analysis, and molecular imaging, in precision diagnosis and treatment. Finally, we critically examine the limitations of current research, including interspecies variability, model constraints, and clinical translation barriers, and discuss the translational potential of microglia-targeted therapies in protecting and restoring clinically meaningful visual function.

21 November 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
NSNannan Shi
Nannan Shi
JLJiaxian Li
Jiaxian Li
MSMengqiu Shang
Mengqiu Shang
WZWeidao Zhang
Weidao Zhang
KXKai Xu
Kai Xu
LLLina Liang
Lina Liang
Background: Geographic atrophy (GA), the endpoint of dry age-related macular degeneration (AMD), is irreversible. The recent approval by the Food and Drug Administration of a complement component 3 inhibitor marks a significant breakthrough, highlighting the critical importance of early detection and management of GA. Consequently, there is an urgent and unmet need for efficient, accurate, and accessible methods to identify and monitor GA. Artificial intelligence (AI), particularly deep learning (DL), applied to noninvasive retinal imaging, offers a promising solution for automating and enhancing GA management. Objective: This systematic review aimed to assess the performance of AI using noninvasive imaging modalities and compare it with clinical expert assessment as the ground truth. Methods: Two consecutive searches were conducted on PubMed, Embase, Web of Science, Scopus, Cochrane Library, and CINAHL. The last search was performed on October 5, 2025. Studies using AI for GA secondary to dry AMD via noninvasive retinal imaging were included. Two authors worked in pairs to extract the study characteristics independently. A third author adjudicated disagreements. Quality Assessment of Diagnostic Accuracy Studies-AI and Prediction Model Risk of Bias Assessment Tool (PROBAST) were applied to evaluate the risk of bias and application. Results: Of the 803 records initially identified, 176 were found through an updated search. Subsequently, 200 papers were assessed in full text, of which 41 were included in the final analysis, 10 for GA detection, 20 for GA assessment and progression, and 11 for GA lesion prediction. The reviewed studies collectively involved at least 24,592 participants (detection: n=7132, assessment and progression: n=14,064, and prediction: n=6706), with a wide age range of 50 to 94 years. The studies spanned a diverse array of countries, including the United States, the United Kingdom, China, Austria, Australia, France, Israel, Italy, Switzerland, and Germany, as well as a multicenter study encompassing 7 European nations. The studies used a variety of imaging modalities to assess GA, including color fundus photography, fundus autofluorescence, near-infrared reflectance, spectral domain–optical coherence tomography (OCT), swept-source (SS)-OCT, and 3D-OCT. DL algorithms (eg, U-Net, ResNet50, EfficientNetB4, Xception, Inception v3, and PSC-UNet) consistently showed remarkable performance in GA detection and management tasks, with several studies achieving performance comparable to clinical experts. Conclusions: AI, particularly DL-based algorithms, holds considerable promise for the detection and management of GA secondary to dry AMD with performance comparable to ophthalmologists. This review innovatively consolidates evidence across GA management—from initial detection to progression prediction—using diverse noninvasive imaging. It has strong potential to augment clinical decision-making. However, to realize this potential in real-world settings, future research is needed to robustly enhance reporting specifications, ensure data diversity across populations and devices, and implement rigorous external validation in prospective, multicenter studies.